A detailed history of Kempen Capital Management N.V. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Kempen Capital Management N.V. holds 4,686 shares of VRTX stock, worth $2.22 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
4,686
Previous 6,533 28.27%
Holding current value
$2.22 Million
Previous $2.66 Million 26.34%
% of portfolio
0.02%
Previous 0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $753,003 - $823,909
-1,847 Reduced 28.27%
4,686 $1.96 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $413,658 - $495,280
-1,206 Reduced 15.58%
6,533 $2.66 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $431,517 - $462,498
-1,276 Reduced 14.15%
7,739 $2.69 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $1.17 Million - $1.31 Million
-3,710 Reduced 29.16%
9,015 $3.17 Million
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $225,734 - $257,510
797 Added 6.68%
12,725 $4.01 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $329,767 - $370,987
1,154 Added 10.71%
11,928 $3.44 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $165,667 - $184,845
-605 Reduced 5.32%
10,774 $3.12 Million
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $103,382 - $128,722
440 Added 4.02%
11,379 $3.21 Million
Q1 2022

May 13, 2022

BUY
$221.42 - $260.97 $2.37 Million - $2.79 Million
10,694 Added 4364.9%
10,939 $2.86 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $5,441 - $6,089
30 Added 13.95%
245 $44,000
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $40,310 - $47,536
215 New
215 $43,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Kempen Capital Management N.V. Portfolio

Follow Kempen Capital Management N.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kempen Capital Management N.V., based on Form 13F filings with the SEC.

News

Stay updated on Kempen Capital Management N.V. with notifications on news.